An upstart jumps almost overnight from preclinical to PhI with a $35M Takeda deal and a buyout option
Here’s a nontraditional way to set up a biotech company and shoot straight at a buyout.
About six years ago, Ingrid Swanson Pultz advised a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
